Skip to main content

Table 1 Patient demographics and clinical characteristics by study group

From: Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes

 

Metformin

Non metformin

Non diabetic

P-value

(n = 202)

(n = 184)

(n = 6,581)

Number

%

Number

%

Number

%

Age at operation, years

       

 Median (range)

55(10.5)

 

59(10.2)

 

46(9.6)

 

<0.001

 <50

68

33.7

40

21.7

4370

66.4

 

 ≥50

134

66.3

144

78.3

2211

33.6

 

Body mass index, kg/m 2

       

 <18.5

0

0

4

2.2

242

3.7

<0.001

 ≥18.5, <25

84

41.6

75

40.8

4644

70.8

 

 ≥25

118

58.4

105

57.1

1669

25.5

 

Serum glucose, mg/dL

       

 Median

165.5

 

150.5

    

 ≤150

83

40.7

93

50

  

0.068

 >150

121

59.3

93

50

   

HbA1C, %

       

 <7

51

32.1

29

35.8

  

0.566

 ≥0.5108

67.9

52

64.2

    

Tumor size, cm

       

 ≤2

100

49.5

93

50.5

3535

53.7

0.356

 >2

102

50.5

91

49.5

3046

46.3

 

Node metastasis

       

 No

110

54.5

110

59.8

3860

58.7

0.463

 Yes

92

45.5

74

40.2

2721

41.3

 

Chemotherapy

       

 No

66

32.7

80

43.5

1799

27.3

<0.001

 Yes

136

67.3

104

56.5

4782

72.7

 

Endocrine therapy

       

 No

58

28.7

54

29.3

2013

30.6

0.801

 Yes

144

71.3

130

70.7

4568

69.4

 

Subgroup according to IHC using ER, PR and HER2

       

 Hormone receptor+, HER2-

107

53.0

98

53.3

3390

51.5

0.385

 Hormone receptor+, HER2-

27

13.4

18

9.8

916

13.9

 

 Hormone receptor-, HER2+

35

17.3

25

13.6

928

14.1

 

 Hormone receptor-, HER2-

33

16.3

43

23.4

1347

20.5

 
  1. HER2, human epidermal growth factor receptor-2; ER, estrogen receptor; PR, progesterone receptor; HbA1c, hemoglobin A1C